Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5807850 | 0.93 | PIK3CD (0.33) | ELANEROCK2MCHR1 | |
| SCHEMBL5762196 | 0.87 | CHRNA7 (0.39) | ELANEROCK2MCHR1 | |
| SCHEMBL5846130 | 0.86 | POLB (0.39) | ELANEROCK2MCHR1 | |
| SCHEMBL5846134 | 0.86 | ELANE (0.41) | ELANE | |
| SCHEMBL5762922 | 0.84 | MCHR1 (0.47) | ROCK2MCHR1KDM4ERAB9AL3MBTL1 | |
| SCHEMBL5762169 | 0.82 | MCHR1 (0.38) | ELANEROCK2MCHR1 | |
| SCHEMBL5760136 | 0.81 | ROCK2 (0.51) | ROCK2MCHR1 | |
| SCHEMBL5790143 | 0.81 | ROCK2 (0.39) | ROCK2MCHR1 | |
| SCHEMBL5759920 | 0.80 | TRPV1 (0.42) | ROCK2MCHR1 | |
| SCHEMBL5763103 | 0.79 | HPGD (0.43) | ROCK2KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638932-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | claimed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | claimed |
| WO-2004110994-A1 | NOVEL PIPERAZINYL-ARYLOXY AND PIPERAZINYL-HETEROARYLOXY-N-ARYL LACTAMS | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266781-A1 | Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams | OPRD1, HTR5A, PTGDR | ELANE 4255/4885ROCK2 3762/4885MCHR1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.